Highest-materiality recent filing
AccuStem submits Medicare coverage application for MSC lung cancer test; enters Novitas review
Submitted local coverage determination to Novitas Solutions for MSC test reimbursement.
AccuStem Sciences amends 8-K to correct name of independent accounting firm
Amendment to Dec 30, 2024 8-K solely to revise the name of the independent registered public accounting firm.
AccuStem Sciences appoints Mercurius LLP as new auditor
Mercurius LLP appointed as AccuStem Sciences' independent registered public accounting firm effective June 17, 2024.
Auditor Mazars USA LLP resigns; company seeks replacement
Mazars to resign effective with Q1 2024 10-Q filing, no later than May 31, 2024.
COO Jeff Fensterer resigns effective June 16; will become consultant
Jeff Fensterer resigned as COO for personal reasons, effective June 16, 2023.
AccuStem Sciences furnishes corporate presentation for investor meetings
Company intends to conduct meetings with third parties using a corporate slide presentation.
AccuStem Sciences appoints Sean McDonald as independent director; board now five members
Sean McDonald appointed to AccuStem board effective Nov. 14, 2022; board expanded from four to five members.
AccuStem Sciences stockholders approve reverse stock split authorization at annual meeting
Elected directors Wendy Blosser, Gabriele Cerrone, Willy Simon, John Brancaccio with >7M votes each.
Director Kunwar Shalubhai resigns from AccuStem board effective June 20, 2022
Dr. Kunwar Shalubhai resigned as member of the Board, effective immediately on June 20, 2022.
Tiziana Life Sciences purchased 1,337,970 shares of AccuStem common stock at $2.00 per share for gross proceeds of $2,675,940.
AccuStem Sciences appoints Wendy Blosser as CEO with $425k salary and options
Wendy Blosser appointed CEO effective March 4, 2022.
Accustem Sciences redomiciled from UK to Delaware via court-approved scheme of arrangement
Redomiciled from UK to Delaware via court-approved scheme of arrangement effective Dec 1, 2021.
On June 5, 2023, Jeff Fensterer, the Chief Operating Officer of AccuStem Sciences Inc. (the “Company”) resigned his position with the Company for personal reasons, effective as of June 16, 2023.
On November 14, 2022, the Board of Directors (the “Board”) of AccuStem Sciences, Inc. (the “Company”) increased the size of the Board to five members and elected Sean McDonald as an independent director, for a term continuing to the Company’s next annual meeting of shareholders, when all directors will be subject to election by shareholders.
On June 20, 2022, Dr. Kunwar Shalubhai notified AccuStem Sciences Inc. (the “Company”) of his decision to resign as a member of the Board, effective immediately.
On March 30, 2022, the Board of Directors of the Company appointed Wendy Blosser, the Company’s Chief Executive Officer as a director to serve on the Board and to hold office until the next annual meeting of stockholders and until her successor is duly elected and qualified
Pursuant to an agreement dated February 18, 2022 (the “Offer Letter”), Wendy Blosser was appointed Chief Executive Officer of AccuStem Sciences, Inc. effective March 4, 2022 (the “Effective Date”).
Max materiality 0.70 · Median 0.50 · Most common event other_material